STUB1 and plasma cell myeloma: Furthermore, research by Rhee et al. has shown that in multiple myeloma patients with CHIP undergoing HCT, there is a significant increase in the incidence of cardiovascular diseases post-transplant, underscoring the prognostic value of pre-HCT CHIP as a potential biomarker for cardiovascular risk assessment [60].